

Appl. No. : 10/783,053  
Filed : February 19, 2004


### PENDING CLAIMS

1.-61. (Previously Canceled).

62.-109. (Cancelled)

110. (New) A method of inhibiting in-vitro replication of HIV comprising providing an effective amount of alpha hydroxyglycinamide or a pharmaceutically acceptable salt of alpha hydroxyglycinamide to a cell culture infected with HIV.

111. (New) The method of claim 110, wherein a compound of formula



112. (New) The method of claim 110, further comprising measuring the presence or absence of HIV or a marker thereof in said cell culture.

113. (New) The method of Claim 112, wherein the presence or absence of HIV is measured by a p24 detection assay.

114. (New) The method of Claim 112, wherein the presence or absence of HIV is measured by reverse transcriptase activity.

115. (New) The method of Claim 112, wherein the presence or absence of HIV is measured by syncytia formation.

116. (New) The method of Claim 110, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a septum sealed vial.

**Appl. No.** : 10/783,053  
**Filed** : February 19, 2004

117. (New) The method of Claim 110, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a container comprising a certification that said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is a good manufacturing practice (GMP) formulation.

118. (New) The method of Claim 110, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a container comprising indicia of approval from a government agency.

119. (New) The method of claim 111, further comprising measuring the presence or absence of HIV or a marker thereof in said cell culture.

120. (New) The method of Claim 119, wherein the presence or absence of HIV is measured by a p24 detection assay.

121. (New) The method of Claim 119, wherein the presence or absence of HIV is measured by reverse transcriptase activity.

122. (New) The method of Claim 119, wherein the presence or absence of HIV is measured by syncytia formation.

123. (New) The method of Claim 111, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a septum sealed vial.

124. (New) The method of Claim 111, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a container comprising a certification that said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is a good manufacturing practice (GMP) formulation.

**Appl. No.** : 10/783,053  
**Filed** : February 19, 2004

125. (New) The method of Claim 111, wherein said alpha hydroxyglycinamide or said pharmaceutically acceptable salt of alpha hydroxyglycinamide is provided in a container comprising indicia of approval from a government agency.